α硫辛酸联合西地那非治疗糖尿病性勃起功能障碍的疗效观察

选择68例糖尿病性勃起功能障碍患者,随机分成2组,每组34例。治疗组给予α硫辛酸静滴,西地那非片口服。对照组单用西地那非片口服,疗程均为2周。观察2组治疗后的临床疗效。结果2组治疗前后的FPG、2hPG及血清睾酮差异均无统计学差异（均P〉0．05）。治疗组有效率（79．4％）与对照组总有效率（55．9％）差异有统计学意义（P〈0．05）。治疗后IIEF-5评分均较治疗前有显著提高（P〈0．05）,治疗后2组间IIEF-5评分差异无统计学意义（P〉0．05）,治疗后3个月治疗组较对照组IIEF-5评分有显著提高。结论α硫辛酸联合西地那非治疗糖尿病性勃起功能障碍较单用西地那非疗效显著。     

十一酸睾酮治疗对老年男性迟发性性腺功能减退症患者血清性激素结合球蛋白水平的影响

目的探讨十一酸睾酮治疗对老年迟发性性腺功能减退症(LOH)患者血清性激素结合球蛋白(SHBG)水平的影响并进行预后因素的(COX)分析。方法将门诊收治的89例老年男性LOH患者随机分为对照组(44例)和观察组(45例),均给予十一酸睾酮连续治疗4 w,仅观察组加用他达拉非治疗,分析两组治疗前、4 w后的国际勃起功能指数评分5(IIEF-5)、血清睾酮(T)、游离睾酮(FT)、双氢睾酮(DHT)、雌二醇(E2)及SHBG水平和前列腺功能。同时记录治疗期间的不良反应,并采用多因素COX分析影响治疗效果的因素。结果两组治疗后的IIEF-5评分、血清激素、SHBG及前列腺特异性抗原(PSA)水平均优于治疗前(均P<0.05)。观察组治疗后的IIEF-5评分高于对照组(均P<0.05);与对照组治疗后相比,观察组的血浆T、FT、DHT、E2、总PSA(T-PSA)和游离PSA(F-PSA)水平升高,SHBG降低(均P<0.05);两组治疗后的前列腺功能及不良反应发生率的差异均无统计学意义(P>0.05)。COX分析发现影响十一酸睾酮治疗对老年LOH的因素有年龄、治疗前T水平、治疗前IIEF-5评分、勃起功能障碍及治疗方案。结论十一酸睾酮对老年男性LOH的治疗效果较好,可同时改善症状并降低血清SHBG水平,对前列腺的功能无影响,但联合他达拉非与否是影响十一酸睾酮疗效的因素。     

睾酮联合血府逐瘀片对中老年男性代谢综合征患者血管内皮与勃起功能的影响

目的观察睾酮联合血府逐瘀片对中老年男性代谢综合征(MS)患者血管内皮与勃起功能的影响。方法 86例MS伴勃起功能障碍(ED)患者随机分为研究组(45例,采用十一酸睾酮胶丸联合血府逐瘀片治疗)、对照组(41例,单用十一酸睾酮胶丸治疗),6个月后观察两组治疗前后ED病情分级与IIEF-5评分、血清超敏C反应蛋白(hs-CRP)、一氧化氮(NO)、内皮素(ET)-1水平、血液流变学、性激素与主要糖脂代谢指标的变化情况以及治疗对血尿常规、前列腺特异性抗原(PSA)、国际前列腺症状评分(IPSS)、肝肾功能的影响作用。结果治疗后研究组与对照组IIEF-5评分、ED分级、血清NO、总睾酮(TT)、游离睾酮(FT)、睾酮分泌指数(TSI)、性激素结合球蛋白(SHBG)、高密度脂蛋白胆固醇(HDL-C),血液流变学均不同程度的改善、而甘油三酯(TG)、空腹血糖(FBG)、空腹胰岛素(Fins)、ET-1均不同程度降低(P<0.001或P<0.05),研究组疗效显著优于对照组(P<0.001)。结论睾酮联合血府逐瘀片治疗MS合并ED能明显改善患者TT与FT水平、改善血管内皮功能与勃起功能、改善糖脂代谢降低胰岛素抵抗,减轻患者的慢性炎症状态,未见明显的补充睾酮治疗的副作用。     

糖尿病视网膜病变与勃起功能障碍的关系

目的探讨糖尿病视网膜病变（DR）与勃起功能障碍（ED）的关系。方法对2型糖尿病（T2DM）合并视网膜病变组（DR组）22例、T2DM无视网膜病变组（非DR组）92例用国际勃起功能指数（IIEF）评分,比较两组间的评分情况。结果DR组的评分明显低于非DR组（P〈0．05）,DR组的ED发生率明显高于非DR组（P〈0．05）。结论糖尿病视网膜病变与ED的发生密切相关。     

胰岛素强化治疗对糖尿病性勃起功能障碍的疗效观察

目的 探讨胰岛素强化治疗对糖尿病性勃起功能障碍（ED）的治疗效果.方法 使用勃起功能国际问卷（IIEF-5）诊断ED,将116例糖尿病性ED患者分为胰岛素组和口服药组,分别予胰岛素和口服药治疗6个月,治疗前后测定血糖、血清睾酮,并进行IIEF-5评分.结果 治疗后胰岛素组患者的空腹血糖（FBG）和糖化血红蛋白（HbAlc）较治疗前明显降低,IIEF-5评分明显升高.治疗后胰岛素组患者的FBG和HbAlc较口服药组降低,IIEF-5评分较口服药组明显升高.结论 胰岛素强化治疗能明显提高糖尿病性ED患者的勃起功能,其疗效优于口服药.     

枸橼酸爱地那非治疗勃起功能障碍的疗效和安全性观察

目的评价临床枸橼酸爱地那非治疗男性勃起功能障碍（ED）的安全性和疗效。方法32例ED患者,其中24例予枸橼酸爱地那非60mg口服（观察组）,8例仅予安慰剂（对照组）。采用国际勃起功能指数表（IIEF-5）量表评价治疗效果,同时记录观察患者自签署知情同意书开始至最后一次随访之间,所发生的任何与治疗目的无关的事件。结果观察组治疗后IIEF-5量表总得分为（24．09±5．05）分,与治疗前的（14．75±3．61）分相比,P〈0．05;与对照组治疗后的（19．86±4．56）分相比,P〈0．05。与药物相关的主要不良事件有头晕、头痛、面部潮红和恶心,严重程度为轻至中度,呈一过性,无需处理。结论口服枸橼酸爱地那非60mg治疗ED安全、有效。     

弥可保联合α-硫辛酸治疗糖尿病勃起功能障碍疗效观察

目的观察弥可保联合α-硫辛酸治疗糖尿病勃起功能障碍患者的疗效。方法将86例糖尿病勃起功能障碍患者随机分为对照组（给予常规改善循环治疗）和弥可保联合α-硫辛酸治疗的观察组,应用勃起功能障碍国际指数（IIEF-5）问卷表评分比较两组患者的治疗效果。结果观察组患者IIEF-5评分改善明显优于对照组,差异有统计学意义（P〈0．05）。结论弥可保联合α-硫辛酸治疗糖尿病患者的勃起功能障碍安全、有效。     

小剂量他达拉非联合十一酸睾酮治疗中老年男性迟发性性腺功能减低伴勃起功能障碍的临床研究

<正>男性雄激素水平随着年龄的增长而进行性下降,易出现勃起功能障碍(ED),性欲减低、易怒、抑郁等多种症状[1]。迟发性性腺功能减退(LOH)常伴有ED等多种症状[2],此类病人单纯使用5型磷酸二酯酶(PDE5)抑制剂治疗效果欠佳。本研究采用小剂量他达拉非联合十一酸睾酮治疗中老年男性LOH伴ED病人,取得良好的临床效果。现报道如下。     

老年胰岛素抵抗与男性勃起功能的相关性研究

目的探讨老年胰岛素抵抗（IR）与男性勃起功能之间的相关关系。方法选取IR指数HomA-IR〉2．8的200例患者，进行相关血生化及前列腺彩色超声检测，并记录基础疾病。并用勃起功能国际指数（IIEF-5）评估这些患者的勃起功能，用统计学方法分析它们之间的相关关系。结果患ED的总发生率为47％，包括轻度ED20．5％，中度ED7．5％，重度ED19．0％。200例患者中高血压46例，其ED发病率37％（17／46例）；肥胖24例，其ED发生率38％（9／24例）；冠心病50例，其ED发生率40％（20／50例）；血脂异常（LDL-CT↑、HDL-C↓）30例，其ED发生率ED47％（14／30例）；糖尿病分别为50例，其ED发生率68％（34／50例）。66例良性前列腺增生（BPH）患者ED总发生率39．39％（26／66例）。相关性分析显示：年龄与勃起功能评分之间呈负相关（r=-0．48，P≤0．05）；血脂异常（LDL-CT↑、HDL-C↓）、冠心病、高血压、肥胖、糖尿病与勃起功能评分之间呈负相关（r值分别为-0．33，-0．41，-0．45，-0．47，-0．51，P≤0．05）；FBG、FINS、HomA-IR、BPH、长期服用降压药物与勃起功能评分之间呈负相关（r值分别-0．23，-0．31，-0．32，-0．41，-0．43，P≤0．05）；HDL-C与勃起功能评分之间呈正相关（r=0．43，P≤0．05）。结论年龄、肥胖、冠心病、高血压、血脂异常和糖尿病是影响男性勃起功能的重要因素。其中HomA-IR上升是ED的重要的危险因素；HDL-C为保护因素。HOMA-IR、WHR、BPH、TC／HDL-C比值和HDL-C水平的检测都是预测ED发生的敏感指标。     

老年勃起功能障碍与下尿路症状相关性的研究

目的了解老年勃起功能障碍（ED）患者的下尿路症状（LUTS）程度,评估ED与LUTS之间的相关性。方法对67例老年ED患者按照国际前列腺症状评分（I-IPS）分为轻度、中度、重度LUTS 3组,比较3组间国际勃起功能指数-5（IIEF-5）评分和阴茎海绵体动脉的收缩期最大血流速率（PSV）和舒张末期血流速率（EDV）。结果3组间随着LUTS程度逐渐加重,IIEF-5评分、PSV呈下降趋势,其中轻度LUTS组与中度、重度LUTS组间比较差异均有统计学意义（P〈0.05）。3组间EDV比较差异无统计学意义（P〉0.05）。结论老年ED患者性生活的质量与LUTS程度相关,对阴茎血流动力学的影响可能是LUTS影响ED程度的途径。     

低剂量甲睾酮和安雄治疗老年男性骨质疏松患者的对比研究

目的 比较低剂量甲睾酮及安雄(十一酸睾酮)对老年男性骨质疏松患者骨密度、生命质量的影响及安全性. 方法 选择血清游离睾酮水平低于正常值的老年男性骨质疏松患者134例,按用药方案分为甲睾酮组45例,甲睾酮1 mg,1次/d舌下含服;安雄组46例,安雄40 mg,1次/d口服;对照组43例,安慰剂,1次/d舌下含服.治疗时间为1年.测定治疗前后骨密度、骨代谢相关血和尿生化指标、生命质量指标和前列腺B超、血清前列腺特异抗原、血尿常规、肝肾功能等. 结果 低剂量甲睾酮和安雄均可防止老年男性骨质疏松患者各部位骨密度进一步下降(均为P＜0.05),股骨颈骨密度在甲睾酮组和安雄组治疗前后差值分别为(0.14±0.18)g/cm2和(0.12±0.09)g/cm2(P＜0.05);安雄治疗在升高血游离睾酮[(32.5±14.2)ng/L]水平作用强于甲睾酮((19.3±9.2)ng/L](P＜0.05);两种激素均能改善患者总体健康、情绪角色功能和精力,低剂量安雄治疗在改善躯体健康和躯体角色功能方面优于低剂量甲睾酮. 结论 低剂量甲睾酮和安雄均可用于老年男性骨质疏松的治疗,同时可提高其生命质量,是一种安全、有效的治疗选择.     

Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing

Because most men with erectile dysfunction have underlying vascular disease, it is important to update the cardiovascular safety profile of medications used in the treatment of erectile dysfunction. This retrospective analysis evaluated serious cardiovascular treatment-emergent adverse events (CVTEAEs) reported in 36 clinical trials of tadalafil, a phosphodiesterase-5 inhibitor used for the treatment of erectile dysfunction. A serious CVTEAE was defined as myocardial infarction, cardiovascular death, or cerebrovascular death. In the 36 trials, 12,487 men (mean age 55 years) with erectile dysfunction received tadalafil, with 5,771 patient-years (PYs) of exposure, and 2,047 men (mean age 56 years) received placebo, with 460 PYs of exposure. Tadalafil 2 to 50 mg was taken as needed, 3 times/week, or once a day. Co-morbidities at baseline included hypertension (31%), diabetes (21%), hyperlipidemia (17%), and coronary artery disease (5%). Across all trials, the incidence rate of serious CVTEAEs was 0.40/100 PYs in tadalafil-treated patients and 0.43/100 PYs in placebo-treated patients. In patients taking tadalafil as needed, 3 times/week, or once a day, the incidence rates of serious CVTEAEs ranged from 0.17 to 0.54/100 PYs across placebo-controlled and open-label trials. In conclusion, the incidence rates of serious CVTEAEs were comparable among men with erectile dysfunction taking tadalafil as needed, 3 times/week, or once a day, and these rates were also comparable with those in placebo-treated patients. In this clinical trial population of men with erectile dysfunction, tadalafil was not associated with an increased risk for serious cardiovascular adverse events.     

Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials

Aims/hypothesis A retrospective analysis of pooled data from twelve placebo-controlled trials was conducted to characterise the efficacy and safety of tadalafil for the treatment of erectile dysfunction in men with diabetes compared with that in men without diabetes.Methods Patients were randomly allocated to tadalafil 10 mg, 20 mg, or placebo, taken as needed for 12 weeks. The study population comprised 637 men with diabetes (mean age 57 years) and 1681 men without diabetes (mean age 56 years).Results At baseline, patients with diabetes had more severe erectile dysfunction than patients without diabetes, with mean International Index of Erectile Function (IIEF) erectile function domain scores of 12.6 and 15.0 respectively (p<0.001). Compared with placebo, tadalafil 10 mg and 20 mg improved all primary efficacy outcomes in both patient groups (p<0.001). Men with diabetes receiving tadalafil 20 mg experienced a mean improvement of 7.4 in their IIEF erectile function domain score against baseline versus 0.9 for placebo (p<0.001). This group reported on average that 53% of their attempts at intercourse were successful, compared with 22% for placebo (p<0.001 for the change from baseline). Baseline IIEF erectile function domain scores correlated inversely with baseline HbA₁c levels. The responses to tadalafil were similar regardless of levels of baseline glycaemic control, diabetic therapy received, or previous use of sildenafil.Conclusions/interpretation Despite more severe baseline erectile dysfunction in men with diabetes, tadalafil was efficacious and well tolerated in this population. As reported for other phosphodiesterase 5 inhibitors, the response to tadalafil was slightly lower in men with diabetes than in men without diabetes.Conflict of interest statement: Funding for the studies and these analyses was provided by Lilly ICOS LLC. Drs Fonseca and Seftel did not receive any compensation from the sponsor for this analysis and the writing of this paper. Dr Fonseca does not have any conflicts of interest to declare. Dr Seftel is a consultant to Auxilium, Bayer, ICOS, LillyICOS LLC and Pfizer.     

Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels

OBJECTIVE: To investigate the effects of prolonged inhibition of phosphodiesterase type-5, using once-daily long-acting phosphodiesterase type-5 inhibitor (tadalafil) on erectile function and biomarkers of endothelial function in male patients with systemic sclerosis (SSc) and erectile dysfunction (ED). METHODS: In an open-label study, 14 nonconsecutive male patients with SSc with different degrees of ED were enrolled into the study irrespective of their clinical response to tadalafil, and received once-daily tadalafil 10 mg for 12 weeks. Primary endpoints were variations from baseline of penile arterial inflow [peak systolic velocity (PSV, cm/s); measured with dynamic color duplex ultrasound] and the erectile function domain score (measured with the International Index of Erectile Function questionnaire). Secondary endpoints were variations from baseline of morning erections (determined by modified question 13 of the Structured Interview on Erectile Dysfunction questionnaire) and plasma concentrations of endothelin-1 (ET1). RESULTS: The PSV and the erectile function domain score were significantly improved by once-daily tadalafil (from 21.3 +/- 6.4 to 30.0 +/- 7.0 cm/s and from 13.0 +/- 6.8 to 17.0 +/- 9.0 vs baseline, respectively; p <0.05). Question 13 scores decreased dramatically after treatment compared with baseline (from 2.2 +/- 0.2 to 0.8 +/- 0.5 arbitrary units; p < 0.001), and plasma ET1 levels decreased (from 24 +/- 15 to 9.8 +/- 7.4 pg/ml; p < 0.05). CONCLUSION: In men with SSc-related ED, once-daily tadalafil improved both erectile function and vascular measures of cavernous arteries. Increases in morning erections and decreases in plasma ET1 levels were found, which may play a potential role in preventing progression of penile fibrosis and erectile dysfunction.     

Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition

INTRODUCTION: The introduction of phosphodiesterase-5 inhibitors as sildenafil, tadalafil, or vardenafil, has tremendously improved the treatment of erectile dysfunction. Patients with the common comorbidity of cardiovascular disease and erectile dysfunction, however, are at risk for critical hypotension in case of self-treatment of cardiac angina with nitrates after the intake of a phosphodiesterase-5 inhibitor. METHODS: We evaluated the safety of 5 mg sublingual nitrendipine after pre-treatment of 8 healthy male volunteers (42.1+/-9.6 yrs) with 20 mg tadalafil. Randomly four different protocols were compared using six hours blood pressure recordings: (1) baseline, (2) 20 mg tadalafil, (3) 5 mg nitrendipine, and (4) 20 mg tadalafil+5 mg nitrendipine. RESULTS: The blood pressure was not significantly affected by tadalafil. Nitrendipine lowered the systolic blood pressure significantly by -1.91 mmHg (p=0.0079). The co-medication of 20 mg tadalafil+5 mg nitrendipine lowered the blood pressure significantly by -2.86 mmHg (p<0.0001). There was no statistically significant difference between tadalafil and nitrendipine (p=0.598). Relevant hypotension (systolic blood pressure of <85 mmHg) was observed in none of the study individuals during the four protocols. CONCLUSIONS: Sublingual nitrendipine seems to be safe for self-treatment of an anginal attack in patients with stable coronary artery disease, who have taken a phosphodiesterase-5 inhibitor. However, our findings on hemodynamic changes in apparently healthy volunteers have to be confirmed in patients with coronary artery disease.     

Tadalafil Administered Once Daily for Treatment of Lower Urinary Tract Symptoms in Korean men with Benign Prostatic Hyperplasia: Results from a Placebo‐Controlled Pilot Study Using Tamsulosin as an Active Control

Objectives: Assess the efficacy and safety of once‐daily tadalafil or tamsulosin versus placebo during 12 weeks on lower urinary tract symptoms (LUTS) in Korean men with benign prostatic hyperplasia (BPH). Methods: Following a 4‐week placebo run‐in period, 151 Korean men were randomly assigned to receive once‐daily tadalafil 5 mg, tamsulosin 0.2 mg, or placebo for 12 weeks. Results: The International Prostate Symptom Score (IPSS) least squares mean changes from baseline to endpoint were numerically but not significantly improved in the tadalafil (?5.8) and tamsulosin (?5.4) groups compared with placebo (?4.2, P > 0.05). Decreases in IPSS obstructive and irritative subscores, IPSS Quality of Life score, and BPH Impact Index from baseline to endpoint were largest in the tadalafil group followed by tamsulosin, though none separated significantly from placebo. Increases in maximum urinary flow rate were small and not significantly different than placebo; the increase was largest in the tadalafil group (2.5 mL/sec), followed by the placebo (2.3 mL/sec) and tamsulosin (2.1 mL/sec) groups. The percentage of subjects reporting at least one treatment‐emergent adverse event was 26.5, 13.7 and 3.9% in the tamsulosin, tadalafil and placebo groups, respectively. Conclusions: In this pilot study in Korean men, those with BPH and treated with tadalafil 5 mg or tamsulosin 0.2 mg once daily experienced a reduction in LUTS, which was numerically (but not statistically) significant compared with the placebo. Tadalafil was well tolerated and few subjects discontinued the study due to treatment‐emergent adverse events. Larger studies in Asian men with BPH and LUTS treated with phosphodiesterase type 5 inhibitors are needed.     

The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval

OBJECTIVES: This study was designed to evaluate effects of tadalafil, a phosphodiesterase-5 inhibitor used for the treatment of erectile dysfunction (ED), on the QT interval. BACKGROUND: Cardiovascular disease is common in men with ED. Men with cardiovascular disease and ED may have decreased cardiac repolarization reserve. METHODS: Effects of tadalafil (100 mg by mouth), ibutilide (0.002 mg/kg intravenously), and placebo on the QT interval in healthy men were compared (placebo and tadalafil [n = 90], with a subset [n = 61] receiving all treatments; mean age 30 years, range 18 to 53 years). Electrocardiographic sampling was done for two days before treatment and on treatment days. The QT was corrected for RR interval with five correction methods, including an individual correction (QTcI). Plasma concentrations of tadalafil were measured to evaluate concentration-QT effect relationships. RESULTS: At the time corresponding to maximum plasma concentration of tadalafil, the mean difference in the change in QTcI between tadalafil and placebo was 2.8 ms; tadalafil was equivalent to placebo (a priori, upper limit of 90% confidence interval < 10 ms [actual = 4.4 ms]; post hoc, upper limit of 95% confidence interval < 5 ms [actual = 4.8]). The active control, ibutilide, significantly increased QTcI by 6.9 and 8.9 ms compared with tadalafil and placebo, respectively. Similar statistical results were obtained with four additional QT correction methods. No subject had a QTcI > or = 450 ms or an increase in QTcI > or = 30 ms with any treatment. CONCLUSIONS: Based on the a priori statistical test of equivalence, placebo and high-dose tadalafil produced equivalent effects on the QT interval. This study reliably discerned 5- to 10-ms changes in corrected QT in the ibutilide active control group.     

Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study

OBJECTIVES: We sought to compare the short-term impact of three different phosphodiesterase-5 (PDE5) inhibitors on pulmonary and systemic hemodynamics and gas exchange parameters in patients with pulmonary arterial hypertension (PAH). BACKGROUND: The PDE5 inhibitor sildenafil has been reported to cause pulmonary vasodilation in patients with PAH. Vardenafil and tadalafil are new PDE5 inhibitors, recently being approved for the treatment of erectile dysfunction. METHODS: Sixty consecutive PAH patients (New York Heart Association functional class II to IV) who underwent right heart catheterization received short-term nitric oxide (NO) inhalation and were subsequently assigned to oral intake of 50 mg sildenafil (n = 19), 10 mg (n = 7) or 20 mg (n = 9) vardenafil, or 20 mg (n = 9), 40 mg (n = 8), or 60 mg (n = 8) tadalafil. Hemodynamics and changes in oxygenation were assessed over a subsequent 120-min observation period. RESULTS: All three PDE5 inhibitors caused significant pulmonary vasorelaxation, with maximum effects being obtained after 40 to 45 min (vardenafil), 60 min (sildenafil), and 75 to 90 min (tadalafil). Sildenafil and tadalafil, but not vardenafil, caused a significant reduction in the pulmonary to systemic vascular resistance ratio. Significant improvement in arterial oxygenation (equally to NO inhalation) was only noted with sildenafil. CONCLUSIONS: In PAH patients, the three PDE5 inhibitors differ markedly in their kinetics of pulmonary vasorelaxation (most rapid effect by vardenafil), their selectivity for the pulmonary circulation (sildenafil and tadalafil, but not vardenafil), and their impact on arterial oxygenation (improvement with sildenafil only). Careful evaluation of each new PDE5 inhibitor, when being considered for PAH treatment, has to be undertaken, despite common classification as PDE5 inhibitors.     

一平苏治疗伴有勃起功能障碍的高血压病人的疗效

目的　观察一平苏对伴有勃起功能障碍(ED)的高血压病人降压及改善ED的疗效。 方法　77例高血压伴器质性血管性阳萎病人随机分成2组一平苏组(39例),接受一平苏片2.5mg～5mgqd.×12w;络活喜组(28例)则作为对照接受络活喜片5mg～10mgqd.×12w。根据治疗前后的BP改变情况评定降压疗效;根据治疗前后2组病人对国际勃起功能指数(IIEF-5)问卷自报评分变化和多普勒血流仪上阴茎-肱动脉收缩压指数(PBI)变化评定2组治疗前后的变化。 结果　2组治疗后不论SBP或DBP均有显著下降(P<0.01),在降低SBP上络活喜略优于一平苏(P<0.05);而在降低DBP上则一平苏略优于络活喜(P<0.05).。治疗后患者IIEF-5答卷评分显示一平苏明显高于络活喜(P<0.01),治疗后多普勒血流仪的PBI比较,一平苏明显高于络活喜(P<0.01)。 结论　一平苏能在降低血压的同时,改善阴茎动脉血供,改善阳蒌症状,适用于治疗伴有ED的男性高血压病人。